Novanta Inc Stock Price, News & Analysis

Novanta (Nasdaq: NOVT) reported its Q2 2025 financial results with revenue increasing 2.2% to $241.0 million. The company posted GAAP net income of $4.5 million and diluted EPS of $0.12, down from $13.8 million and $0.38 respectively in Q2 2024.

Key highlights include 10% growth in bookings and a book-to-bill ratio of 1.02. The Advanced Surgery and Robotics & Automation businesses achieved mid-teens revenue growth. The company secured significant design wins in medical devices and warehouse robotics sectors.

For full-year 2025, Novanta updated guidance to revenue of $970-985 million, Adjusted EBITDA of $225-230 million, and Adjusted EPS of $3.22-3.36. Q3 2025 revenue is expected at $244-247 million.

Novanta (Nasdaq: NOVT), a trusted technology partner to medical and advanced technology equipment manufacturers, has scheduled its second quarter 2025 earnings release and conference call for Tuesday, August 5, 2025.

The conference call will begin at 10:00 a.m. ET. Investors can access the call by dialing (888) 346-3959 or via live webcast through the company's website. A replay will be available on Novanta's website until September 29, 2025.

Novanta Inc. (NOVT), a technology partner specializing in medical and advanced technology equipment manufacturing, has announced that CFO Robert Buckley will present at the CJS Securities 25th Annual New Ideas Summer Conference. The presentation is scheduled for July 10, 2025, and will take place in White Plains, New York. Novanta, which trades on the Nasdaq, provides technology solutions to equipment manufacturers in the medical and advanced technology sectors.

Novanta (Nasdaq: NOVT), a technology partner specializing in medical and advanced technology equipment manufacturing, has announced that its Chief Financial Officer, Robert Buckley, will be presenting at the Baird 2025 Global Consumer, Technology & Services Conference. The presentation is scheduled for June 4, 2025, and will take place in New York, NY.

Novanta (Nasdaq: NOVT), a technology partner specializing in medical and advanced technology equipment manufacturing, has announced that its Chair & CEO Matthijs Glastra will be presenting at the William Blair 45th Annual Growth Stock Conference. The presentation is scheduled for June 3, 2025, and will take place in Chicago, IL.

Novanta (NASDAQ: NOVT) reported solid Q1 2025 financial results with revenue increasing 1.1% to $233.4 million. The company achieved significant growth in GAAP net income, up 45% to $21.2 million, with diluted EPS of $0.59. Adjusted EBITDA rose 1% to $50 million, while operating cash flow was $31.7 million. For Q2 2025, Novanta expects revenue between $230-240 million and Adjusted EBITDA of $50-55 million. The company plans to implement cost containment measures targeting $20 million in annual savings to offset trade policy impacts. Despite macroeconomic uncertainties, management remains confident in meeting full-year EBITDA commitments, supported by new product launches and a recent tuck-in acquisition completed in April.

Novanta Inc. (Nasdaq: NOVT), a trusted technology partner to medical and advanced technology equipment manufacturers, has announced it will release its first quarter 2025 financial results on Tuesday, May 6, 2025.

The company will host a conference call at 10:00 a.m. ET on the same day to discuss the results. Investors can access the call by dialing (888) 346-3959 or join via live webcast through the Events & Presentations page on Novanta's website. An audio replay will be available approximately three hours after the call concludes and remain accessible until June 30, 2025.

Novanta reported its financial results for Q4 and full year 2024. Q4 2024 GAAP revenue increased 13% to $238 million, despite a $2 million unfavorable FX impact. GAAP diluted EPS was $0.46, while adjusted EPS was $0.76. Full year 2024 GAAP revenue rose 8% to $949 million. GAAP diluted EPS was $1.77, and adjusted EPS was $3.08. Adjusted EBITDA for the full year grew 7% to $210 million, and operating cash flow increased 32% to $159 million.

In Q4, organic revenue growth was 3.4%. GAAP operating income was $26.7 million, up from $21.7 million in Q4 2023. GAAP net income was $16.5 million, compared to $12.5 million in Q4 2023. Adjusted EBITDA rose 15% to $52.1 million, and operating cash flow increased 58% to $61.6 million.

For the full year, GAAP operating income was $110.6 million, and GAAP net income was $64.1 million, down from $72.9 million in 2023. Adjusted EBITDA increased to $209.8 million. Net debt was $305.2 million.

For 2025, Novanta projects GAAP revenue of $1 billion, with adjusted EBITDA between $225 million and $235 million, and adjusted EPS between $3.35 and $3.55. Q1 2025 GAAP revenue is expected to be $232 million to $236 million, with adjusted EBITDA between $48 million and $51 million, and adjusted EPS between $0.63 and $0.71.

IDEX (NYSE: IEX) has announced significant changes to its Board of Directors. The company has appointed Stephanie Disher, CEO of Atmus Filtration Technologies, and Matthijs Glastra, Chair and CEO of Novanta Inc., to its Board, effective February 21, 2025. These appointments will increase the Board size from 10 to 12 directors.

Disher will serve on the Nominating and Corporate Governance Committee, while Glastra joins the Audit Committee. Both bring extensive global leadership experience - Disher in finance and operations from her roles at Atmus, Cummins, and BP, and Glastra in international operations, innovation, M&A, and strategy from Novanta and Philips.

Additionally, David Parry and Livingston Satterthwaite will retire from the Board following the 2025 Annual Meeting of Stockholders and will not seek re-election.